China's Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug
29/09/2026 05:44
China's Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug Sept 29 (Reuters) - Jiangsu Hengrui Pharmaceuticals 600276.SS, China's largest drugmaker by market value, said on Tuesday it will license global rights to its weight-management drug HRS-1596 to Novo Nordisk A/S NOVOb.CO in a deal worth up to $2.6 billion.
Under the agreement, Novo Nordisk gains exclusive rights to develop, manufacture and commercialise the drug outside certain regions, with the Danish drugmaker paying an upfront fee of $300 million.
(Reporting by Shivangi Lahiri in Bengaluru; Editing by Harikrishnan Nair)
Recent news on Novo Nordisk A/S
See all newsFocus: Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market
Factbox: Anthropic's public benefit fund and how it compares with other big philanthropic efforts
Novo's CagriSema helped women lose 25% of weight on average, analysis shows
As weight-loss drug users turn to dietary supplements, doctors, regulators raise flags
Factbox: Major drugmakers turn to China for licensing deals